2021 Volume 12 Issue 1 Pages 52-57
Reports reveal that continuous renal replacement therapy (CRRT) circuit lifetime significantly lengthens in patients treated with disseminated intravascular coagulation (DIC) drugs. However, the relationship between a circuit lifetime and DIC drugs is unclear. Therefore, we conducted a retrospective observational study comparing the effectiveness of recombinant human soluble thrombomodulin (rhTM) with that of danaparoid sodium (DS) on circuit lifetime in patients undergoing CRRT. We compared the circuit patency rates between the two groups: TM group (administration of rhTM, n=33) and the DS group (administration of DS, n=65) at 48 and 72 hours. The TM group had a significantly higher result than the DS group at 48 hours. Data obtained was analyzed by matched pair analysis of the two groups with background items that may affect circuit lifetime (83.4% vs 54.7%). However, there was no significant difference at 72 hours (62.4% vs 54.7%). The results indicate that rhTM prevents coagulation in the CRRT circuit compared to DS when circuit replacement period is 48 hours.
